Genmab Long Term Debt

As of the most recent data (March 2026), GMAB shows a long-term debt of $5.1B. That compares with $130M in the prior-year period — up 3820.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GMAB's long-term debt is now $5.1B (was $130M) — a 3820.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Genmab is outperforming or lagging.

Tracking GMAB's long-term debt over time shows whether Genmab is scaling, shrinking, or reshaping that part of the business. The current reading is $5.1B That compares with $130M in the prior-year period — up 3820.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Genmab's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $5.1B) with ownership activity and broader fundamentals.

Genmab's long-term debt is $5.1B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.